Expanding the therapeutic actions of GLP-1 medicines from liver inflammation to prevention or even reversal of fibrosis in the absence of atherosclerosis would provide valuable mechanistic insights into how GLP-1 medicines improve MASH. The gene discussed is GCG; the disease is atherosclerosis.